ACN Newswire
Read More

Malaysian Genomics Signs MoU with Ajlan to explore distribution of biopharmaceutical and genetic screening services in MENA region

indie
3 minutes

PETALING JAYA, Malaysia, Aug 29, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced that the Group has signed a Memorandum of Understanding (MoU) to explore opportunities for the distribution of biopharmaceutical and genomics products and services with Ajlan & Bros Medical Company.Noor Azri Bin Dato' Sri Noor Azerai, Executive Director of Malaysian Genomics, and H.E. Eng. Ali AlHazmi, Group Chief Executive Officer of Ajlan & Bros Holding Group [L-R]Ajlan, based in Riyadh, Saudi Arabia, is part of a multinational conglomerate established in 1979 with extensive global private equity, real estate and industrial investments.As part of the MoU, the parties will explore the feasibility of Ajlan becoming a marketing and distribution representative for Malaysian Genomics for genetic screening tests, mesenchymal stem cell and exosome products. Ajlan will also identify commercial research and development (R&D) opportunities for genome sequencing and analysis in the Middle East and North Africa (MENA) region for areas such as agriculture, aquaculture, plantati...

ACN Newswire
Read More

Malaysian Genomics to Offer First-Ever Sports-Based Tests Specific to Southeast Asian Genetic Profiles

indie
2 minutes

PETALING JAYA, Malaysia, Jul 6, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce that the Group's wholly-owned subsidiary, MGRC Therapeutics Sdn Bhd (MGRCT), is collaborating with Rinani Genotec Sdn Bhd (Genotec) to offer sports-based genetic tests.Genotec, a biomedical technology firm focusing on stem cell treatment and genetic testing, now offers a direct-to-consumer sports and fitness DNA test which enables individuals to better understand their genetic profile in sports and fitness-related areas. The test result includes categories such as energy metabolism and utilisation, muscle performance, response to cardiovascular training, weight management, nutrient metabolism, bone and joint health, and mental ability and performance. The information can then be integrated by individuals into their lifestyle in order to improve their daily sport and fitness performance.The collaboration will see both parties consult and collaborate on sports-based genetic profile testing and the marketing of these services. In addition, Genotec will also work closely with ...

SeaPRwire

Personalised Health Supplements Customised from Genetic Screening Results Offered on airasia Super App

aseanpr
3 minutes

Malaysian Genomics, airasia Super App, Speedoc and Unique Remedy Join Hands to Offer Health Solutions to airasia Super App's 51 Mil Users PETALING JAYA, Malaysia, Apr 6, 2022 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical company, is pleased to announce the launch of its genetic screening plus personalised health supplements solutions on the airasia Super App, the region's leading travel & lifestyle digital platform. Besides airasia Super App, this unique collaboration also includes Speedoc, a virtual clinic and healthcare solutions platform that will provide consultation of test results by their doctors, and MGRC partner Unique Remedy, compounding pharmacy specialist which will produce the personalised health supplements. All genetic screening solutions include the Dtect Wellness genetic screening test complemented with personalised supplements made based on each person's test results. The Dtect Wellness test analyses a person's DNA to identify relevant genetic markers that play important roles in influencing nutrition, health and wellness. Based on the test results, supplements that are deemed most im...

ACN Newswire
Read More

Basecare Announces 2021 Annual Results: Overall Increase in Revenue and Gross Profit

indie
6 minutes

HONG KONG, Mar 31, 2022 - (ACN Newswire via SEAPRWire.com) - Suzhou Basecare Medical Corporation Limited ("Basecare" or the "Company", together with its subsidiaries, the "Group", stock code: 2170), an innovative platform of genetic testing solutions for assisted reproduction in China, announced its audited consolidated results for the year ended 31 December 2021 (the "Year").In 2021, the Group's revenue increased by 32.3% YOY to RMB107 million. Gross profit was RMB51.15 million, representing an increase of 84.6% YOY. The consolidated gross margin increased from 34.2% to 47.7%, mainly due to the increases of the gross profit margin in the PGT-A kits from 46.0% to 70.0%. Basecare, a leading provider of third-generation IVF clinical solutions for assisted reproduction in China, has extended its reach beyond the pre-implantation stage to the prenatal and postnatal stages, and has self-developed kits in each stage, making it a company with a genetic test kit pipeline that covers the full reproductive cycle.A leading position in assisted reproductive in China with core technologyBasecare's PGT-A kit is the first third-generation IVF genetic testing kit that has been approved by the Nati...

JCN Newswire
Read More

Fujitsu, Kyoto University Develop Explainable AI Verification System for Estimating Disease-Causing Potential of Genetic Mutations

ruth
9 minutes

TOKYO, Mar 11, 2021 - (JCN Newswire via SEAPRWire.com) - Fujitsu Limited and a Kyoto University research group led by Professor Yasushi Okuno of the Kyoto University Graduate School of Medicine, has developed an AI verification system called "MGeND Intelligence". When the genetic mutation(1) information of a patient is input into this system, its ability to cause disease is estimated by pathogenicity estimation AI using machine learning technology and the explanatory text of the basis of this finding is generated and displayed together with the estimated result by the explainable AI. This explanation offers a useful reference to doctors who are considering a treatment plan or genomic medical researchers. The system draws from the "Integrated Database of Clinical and Genomic Information program"(2), managed by the Japan Agency for Medical Research and Development , and from April 2021, Kyoto University plans to offer MGeND Intelligence to joint researchers and institutions.Fig. 1: System OverviewFig. 2: Flow chart of generation of explanatory text of finding basisIn addition to the pathogenicity estimation AI, the MGeND Intelligence verification system includes explainable AI that s...